Key Drivers
- Net cash
- Margin rebound
- Intangible-heavy assets
AIAI Summary
OMCL now looks more like a cash-generative recovery story than a weak growth name, with strong free cash flow, rising margins, and raised guidance, but the investment case still hinges on proving that the operating leverage is durable amid booking delays, purchase timing noise, and memory-cost pressure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net cash
- •Margin rebound
- •Intangible-heavy assets
OMCL is liquid, net cash positive, and generating strong free cash flow, but its long-term appeal depends on whether the recent margin rebound can offset thin historical profits and an asset-heavy balance sheet.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Overhead Resistance
- •Fragile Trend
Over the last month, OMCL has weakened into a short-term downtrend, holding $36–$38 support but repeatedly failing to reclaim $39.5–$41.4, leaving the chart fragile unless $35.37 breaks.
Rebounded off $35.37 and stabilized in the $36-$38 range, but upside attempts keep stalling below resistance
Sentiment & News
Key News Insights:
- •Q2 Beat
- •Bookings Delays
- •Margin Pressure
Omnicell beat Q2 expectations and raised its full-year outlook on strong product momentum, but delayed hospital purchasing, softer bookings, and rising memory-chip costs are pressuring near-term execution.
The news is modestly positive for fundamentals but likely keeps the stock range-bound until bookings and cost trends improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings